Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (6584)	6/18/2002 9:29:31 AM
From: tuck	Read Replies (1) \| Respond to of 52153

From Briefing.com, FWIW: >>7:47AM UBS initiates coverage on biotech stocks : UBS Warburg initiates coverage on the biotech sector, saying that recent weakness in the group has resulted in attractive valuations and good buying opportunities; also, firm believes that positive upcoming events-- such as earlier than expected approval of DNA's Avastin or approval of MEDI's FluMist in time for the flu season-- could improve investor sentiment and expand earnings multiples upward toward historical norms; within the group of large-cap profitable co's, Strong Buy-rated stocks are DNA and MEDI, Buy-rated stocks are AMGN, CHIR, GENZ, and IDPH, and BGEN is rated Hold (see Upgrades/Downgrades for full list).<< Cheers, Tuck